Join WuXi Biology Early Discovery Platform's experts as they discuss the innovative and latest technology updates in small and new molecule drug discovery.
The realm of drug discovery is perpetually advancing, with early-stage research playing a crucial role in identifying and developing new therapeutic candidates. At the forefront of this innovation, WuXi Biology Early Discovery Platform continuously develops and refines innovative technologies to push the boundaries of small and new molecule drug discovery. This upcoming launch event will showcase our latest advancements and present updated products aimed at accelerating early-stage drug discovery, reinforcing our dedication to transforming pharmaceutical research.
Join us for an exclusive webinar where experts from WuXi Biology Early Discovery Platform, Dr. Wenji Su, Dr. Zhongyao Ma, and Dr. Andy Ng, will unveil the latest innovative technologies and products in small molecule and new molecule drug discovery. Attendees will gain insights into DELpro 2025, DELight Gen.5, the Direct-to-Biology Platform, Peptide Drug Discovery, the Target Discovery and Validation Platform, and Oligonucleotide Drug Discovery, along with their potential impacts on the drug discovery process. Following the expert presentations, a live Q&A session will allow attendees to engage with the speakers, ask questions, and gain deeper insights into our technologies and their applications.
Presenters
Wenji Su
Dr. Wenji Su earned her BSc from HKUST and PhD in Biochemistry, Cell, and Developmental Biology from Emory University. She worked at GSK before joining WuXi AppTec in 2017. Currently, she heads WuXi Biology's Early Discovery Platform, providing comprehensive early-stage drug discovery services and developing solutions for novel modality discoveries.
Zhongyao Ma
Dr. Zhongyao Ma earned his bachelor’s in Biology from Shanghai Jiao Tong University and a Ph.D. in Genetics and Developmental Biology from the University of Georgia. In 2021, he joined WuXi AppTec's China R&D Center, now focusing on expanding DNA Encoded Library (DEL) technology, and leading peptide discovery and target science platforms.
Andy Ng
Dr. Andy Ng is Director of Oligonucleotide Drug Discovery at WuXi AppTec, focusing on accelerating oligo drug development. He spent 8 years as Director of Preclinical Studies at a biotech firm in Singapore/USA, developing RNA-targeted ASO and small molecules. He earned his Ph.D. in Synthetic Biology from Columbia University and trained at A*STAR.
Sponsor
WuXi AppTec
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
